User login
CHICAGO – In a plenary session at the ASCO 2013 annual meeting, Dr. Richard Gray of the University of Oxford said that when it comes to treating breast cancer patients with tamoxifen "the evidence is now overwhelming."
He presented data from the aTTom trial showing that 10 years of tamoxifen treatment cut these patients' risk of dying of breast cancer in half, when compared with 5 years of treatment.
CHICAGO – In a plenary session at the ASCO 2013 annual meeting, Dr. Richard Gray of the University of Oxford said that when it comes to treating breast cancer patients with tamoxifen "the evidence is now overwhelming."
He presented data from the aTTom trial showing that 10 years of tamoxifen treatment cut these patients' risk of dying of breast cancer in half, when compared with 5 years of treatment.
CHICAGO – In a plenary session at the ASCO 2013 annual meeting, Dr. Richard Gray of the University of Oxford said that when it comes to treating breast cancer patients with tamoxifen "the evidence is now overwhelming."
He presented data from the aTTom trial showing that 10 years of tamoxifen treatment cut these patients' risk of dying of breast cancer in half, when compared with 5 years of treatment.
AT THE ASCO ANNUAL MEETING 2013